CARsgen Therapeutics Holdings Limited
科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2171)

VOLUNTARY ANNOUNCEMENT
SHARE REPURCHASE BY THE COMPANY

This announcement is made by CARsgen Therapeutics Holdings Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**" or "**CARsgen**") on a voluntary basis.

The Company is pleased to announce that a share repurchase plan has been approved by the board of directors of the Company (the "**Board**") to repurchase shares of the Company (the "**Shares**") not exceeding 1% of the total issued Shares in the open market within 150 Hong Kong trading days commencing from May 8, 2025, pursuant to the 2024 Share Repurchase Mandate (as defined below) and, where applicable, the share repurchase mandate to be approved by the shareholders of the Company (the "**Shareholders**") at the upcoming annual general meeting to be held on May 22, 2025 (collectively, "**Share Repurchase Mandates**").

The funds to be used for the share repurchases come from non-IPO raised funds, which include, among others, business development (BD) income, interest income, and other subsidy. The Company shall conduct the share repurchases by exercising its powers under the Share Repurchase Mandates in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and all applicable laws and regulations to which the Company is subject.

As approved by the Shareholders at the annual general meeting held on May 21, 2024, the Company could repurchase up to 10% of the total issued Shares as at the date of passing of such ordinary resolution, being a maximum of 57,564,391 Shares (the "**2024 Share Repurchase Mandate**"). In May and June 2024, the Company repurchased a total of 4,135,500 Shares (the "**Shares Repurchased**") on The Stock Exchange of Hong Kong Limited at the aggregate consideration of approximately HK$24,116,134.85 before expenses. On July 29, 2024, all of the Shares Repurchased were cancelled by the Company.

Shareholders and potential investors should note that the implementation of the on-market share repurchases by the Company will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the timing, quantity, or price of any share repurchases or whether the Company will make any share repurchases at all. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, May 13, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Bingsen GUO, Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.